Histone acetyltransferases regulate HIV-1 enhancer activity in vitro

  1. Philip L. Sheridan1,3,5,
  2. Timothy P. Mayall1,5,
  3. Eric Verdin2,4, and
  4. Katherine A. Jones1,6
  1. 1The Salk Institute for Biological Studies, La Jolla, California 92037-1099; 2The Picower Institute for Medical Research, Manhasset, New York 11030 USA

Abstract

Specific inhibitors of histone deacetylase, such as trichostatin A (TSA) and trapoxin (TPX), are potent inducers of HIV-1 transcription in latently infected T-cell lines. Activation of the integrated HIV-1 promoter is accompanied by the loss or rearrangement of a positioned nucleosome (nuc-1) near the viral RNA start site. Here we show that TSA strongly induces HIV-1 transcription on chromatin in vitro, concomitant with an enhancer factor-assisted increase in the level of acetylated histone H4. TSA treatment, however, did not detectably alter enhancer factor binding or the positioning of nuc-1 on the majority of the chromatin templates indicating that protein acetylation and chromatin remodeling may be limiting steps that occur only on transcriptionally competent templates, or that remodeling of nuc-1 requires additional factors. To assess the number of active chromatin templates in vitro, transcription was limited to a single round with low levels of the detergent Sarkosyl. Remarkably, HIV-1 transcription on chromatin was found to arise from a small number of active templates that can each support nearly 100 rounds of transcription, and TSA increased the number of active templates in each round. In contrast, transcription on naked DNA was limited to only a few rounds and was not responsive to TSA. We conclude that HIV-1 enhancer complexes greatly facilitate transcription reinitiation on chromatin in vitro, and act at a limiting step to promote the acetylation of histones or other transcription factors required for HIV-1 enhancer activity.

Keywords

Footnotes

  • Present addresses: 3Chiron Technologies, San Diego, California 92121-1204 USA; 4The Gladstone Institute/University of California, San Francisco, California 94110 USA.

  • 5 These authors contributed equally to this work.

  • 6 Corresponding author.

  • E-MAIL jones{at}salk.edu; FAX (619) 535-8194.

    • Received August 28, 1997.
    • Accepted October 21, 1997.
| Table of Contents

Life Science Alliance